METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA
First Claim
Patent Images
1. An ophthalmic aqueous solution for treating ocular hypertension and glaucoma, comprising PGF2α
- analogue as an active ingredient, wherein said ophthalmic aqueous solution contains nonionic surfactant, stabilizing agent and substantially no preservatives in a container consisting essentially of polyethylene.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogues in an aqueous composition.
-
Citations
22 Claims
-
1. An ophthalmic aqueous solution for treating ocular hypertension and glaucoma, comprising PGF2α
- analogue as an active ingredient, wherein said ophthalmic aqueous solution contains nonionic surfactant, stabilizing agent and substantially no preservatives in a container consisting essentially of polyethylene.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
13. An ophthalmic aqueous solution comprising
0.0001-0.01% w/v PGF2α - analogue;
0.05-0.5% w/v non-ionic surfactant, 0.005-0.2% w/v stabilizing agent, and optionally buffering agents, pH adjusters and tonicity agents conventionally used in ophthalmic solutions, and substantially no preservatives, in a container consisting essentially of polyethylene or in contact with container material consisting essentially of polyethylene. - View Dependent Claims (16, 17, 18)
- analogue;
-
14. An ophthalmic aqueous solution comprising
0.0010-0.0015% w/v tafluprost; -
0.05-0.1% w/v polysorbate 80, 0.01-0.1% w/v disodium edetate, and optionally buffering agents, pH adjusters and tonicity agents conventionally used in ophthalmic solutions, and substantially no preservatives, in a container consisting essentially of polyethylene or in contact with container material consisting essentially of polyethylene.
-
-
15. An ophthalmic aqueous solution, comprising
0.0015% w/v tafluprost 0.075% w/v polysorbate 80, 0.05% w/v disodium edetate, 2.25% w/v glycerol, 0.2% w/v sodium dihydrogen phosphate dihydrate, pH adjusters, and substantially no preservatives, in a container consisting essentially of polyethylene or in contact with container material consisting essentially of polyethylene.
-
19. A method for increasing aqueous solubility and improving stability of PGF2α
- analogues in an aqueous ophthalmic solution, comprising the steps of preparing an aqueous ophthalmic solution containing PGF2α
analogue, nonionic surfactant, stabilizing agent and substantially no preservatives, and packaging the preservative-free ophthalmic solution in a container consisting essentially of polyethylene or in contact with container material consisting essentially of polyethylene.
- analogues in an aqueous ophthalmic solution, comprising the steps of preparing an aqueous ophthalmic solution containing PGF2α
-
20. (canceled)
-
21. (canceled)
-
22. A method for treating ocular hypertension and glaucoma, which comprises administration of an ophthalmic aqueous solution comprising PGF2α
- analogue as an active ingredient thereof to a subject in need of said treatment, wherein said ophthalmic solution comprises nonionic surfactant, stabilizing agent, and substantially no preservatives.
Specification